Aranesp (darbepoetin alfa), the new longer-acting erythropoietin analog for anemia

You'll see patients getting Aranesp (darbepoetin alfa), the new longer-acting erythropoietin analog for anemia.

Aranesp is approved for anemia associated with chronic renal failure...including patients on dialysis, and those not on dialysis.

It's also being studied for anemia due to cancer chemotherapy.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote